A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
Public ClinicalTrials.gov record NCT02132949. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Multinational, Phase II Study to Evaluate Perjeta in Combination With Herceptin and Standard Neoadjuvant Anthracycline-Based Chemotherapy in Patients With HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This multicenter, non-randomized, open-label, phase 2 study is designed to evaluate the safety and efficacy of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and anthracycline-based chemotherapy as neoadjuvant treatment in participants with HER2-positive locally advanced, inflammatory, or early-stage breast cancer. Each investigator will choose a treatment regimen (A or B) for all of their participants to follow. Treatment regimen A (for Cohort A) will include dose-dense doxorubicin and cyclophosphamide (ddAC), followed by paclitaxel, with pertuzumab and trastuzumab given from the start of paclitaxel. Treatment regimen B (for Cohort B) will include 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), followed by docetaxel, with pertuzumab and trastuzumab given from the start of docetaxel. Participants in both cohorts will subsequently undergo surgical treatment and then resume pertuzumab and trastuzumab treatment.
Study identification
- NCT ID
- NCT02132949
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 401 participants
Conditions and interventions
Conditions
Interventions
- 5-Fluorouracil Drug
- Cyclophosphamide Drug
- Docetaxel Drug
- Doxorubicin Drug
- Epirubicin Drug
- Paclitaxel Drug
- Pertuzumab Drug
- Trastuzumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 14, 2014 (Actual)
- Primary completion
- Mar 3, 2016 (Actual)
- Completion
- Aug 25, 2020 (Actual)
- Last update posted
- Sep 17, 2021
2014 – 2020
United States locations
- U.S. sites
- 24
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of South Alabama; Mitchell Cancer Institute | Mobile | Alabama | 36604 | — |
| Marin Specialty Care | Greenbrae | California | 94904 | — |
| California Pacific Medical Center | San Francisco | California | 94115 | — |
| MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center) | Washington D.C. | District of Columbia | 20007 | — |
| Washington Cancer Institute at MedStar Washington Hospital Center. | Washington D.C. | District of Columbia | 20010 | — |
| Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy) | Jacksonville | Florida | 32256 | — |
| Northwest Georgia Oncology Centers PC - Marietta | Marietta | Georgia | 30060 | — |
| Berkshire Medical Center | Pittsfield | Massachusetts | 01201 | — |
| Allina Health, Virginia Piper Cancer Institute | Minneapolis | Minnesota | 55407 | — |
| Saint Lukes Hospital Cancer Institute | Kansas City | Missouri | 64111 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Regional Cancer Care Associates LLC - Morristown | Morristown | New Jersey | 07962 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| MSKCC @ Commack | Commack | New York | 11725 | — |
| MSKCC @ West Harrison | Harrison | New York | 10604 | — |
| Mount Sinai Beth Israel Comprehensive Cancer Center | New York | New York | 10011 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| MSKC @ Rockville | Rockville Centre | New York | 11570 | — |
| Mercy Clinic Oklahoma Communties, Inc | Oklahoma City | Oklahoma | 73120 | — |
| Harrington Cancer Center | Amarillo | Texas | 79106 | — |
| University of Utah; Huntsman Cancer Hospital | Salt Lake City | Utah | 84112 | — |
| Blue Ridge Cancer Care | Roanoke | Virginia | 24014 | — |
| PeaceHealth St. Joseph Cancer Center | Bellingham | Washington | 98225 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02132949, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 17, 2021 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02132949 live on ClinicalTrials.gov.